Back to Stocks

CWAN

Clearwater Analytics Holdings, Inc.
7 filings tracked
technologycloud computingMID ($2B-10B)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

Clearwater Analytics is rapidly transforming from a specialized accounting provider into a comprehensive operating system for global capital markets.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

The headline revenue growth at Clearwater Analytics obscures a troubling trend of operational inefficiency and rising financial risk. Cost of revenue spiked 123% year-over-year, causing gross margins to contract significantly from 73% to 66%.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every CWAN filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The Q1 2026 filing presents a company at a critical inflection point, balancing aggressive inorganic growth against deteriorating margins. The 74% revenue jump is an undeniable signal of market demand and successful acquisition execution, yet the transition to a debt-funded growth model has introduced substantial volatility to the bottom line. The shift from a high-margin, organic grower to a consolidating powerhouse has temporarily eroded the company's profitability profile, replacing net income with a reliance on Adjusted EBITDA to prove viability. Ultimately, the investment thesis now hinges on the successful closure of the $8.4 billion merger and the ability of management to realize synergies from the Enfusion and Beacon deals. If the company can stabilize gross margins and leverage its $10 trillion asset base to drive cross-selling, the current losses will be viewed as a necessary investment in scale. However, if regulatory hurdles delay the merger or if integration costs continue to outpace revenue gains, the company faces a challenging path to returning to GAAP profitability.

Selected Quarter

Core Takeaway

CWAN is successfully buying market share and scale, but the cost of capital and integration is weighing on GAAP earnings.

Investor Lens

The trade-off is between dominant market scale and the ability to return to GAAP profitability under a heavy debt load.

Watch Next

Australian FIRB approval for the $8.4B merger and Q2 gross margin recovery.

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)-0.12Q2 '26 (10-Q)

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-Q)
bearishMay 7

Company reported a net loss of $2.8 million compared to a profit in the prior year period.

earnings miss
60%
bearishMay 7

Gross margins declined from 73% to 66% due to acquisition integration costs.

margin compression
70%
bullishMay 7

Successful integration of Enfusion and Beacon drove a 74% revenue increase.

acquisition
80%
neutralMay 7

Utilized a new $800M+ credit facility to fund growth, significantly increasing interest expense.

debt restructure
50%
bearishMay 7

Company reported a net loss of $2.8 million compared to a profit in the prior year period.

earnings miss
60%
bearishMay 7

Gross margins declined from 73% to 66% due to acquisition integration costs.

margin compression
70%
bullishMay 7

Successful integration of Enfusion and Beacon drove a 74% revenue increase.

acquisition
80%
neutralMay 7

Utilized a new $800M+ credit facility to fund growth, significantly increasing interest expense.

debt restructure
50%
bearishMay 7

Company reported a net loss of $2.8 million compared to a profit in the prior year period.

earnings miss
60%
bearishMay 7

Gross margins declined from 73% to 66% due to acquisition integration costs.

margin compression
70%
bullishMay 7

Successful integration of Enfusion and Beacon drove a 74% revenue increase.

acquisition
80%
neutralMay 7

Utilized a new $800M+ credit facility to fund growth, significantly increasing interest expense.

debt restructure
50%
bearishMay 7

Company reported a net loss of $2.8 million compared to a profit in the prior year period.

earnings miss
60%
bearishMay 7

Gross margins declined from 73% to 66% due to acquisition integration costs.

margin compression
70%
bullishMay 7

Successful integration of Enfusion and Beacon drove a 74% revenue increase.

acquisition
80%
neutralMay 7

Utilized a new $800M+ credit facility to fund growth, significantly increasing interest expense.

debt restructure
50%
bearishMay 7

Company reported a net loss of $2.8 million compared to a profit in the prior year period.

earnings miss
60%
bearishMay 7

Gross margins declined from 73% to 66% due to acquisition integration costs.

margin compression
70%
bullishMay 7

Successful integration of Enfusion and Beacon drove a 74% revenue increase.

acquisition
80%
neutralMay 7

Utilized a new $800M+ credit facility to fund growth, significantly increasing interest expense.

debt restructure
50%
bearishMay 7

Company reported a net loss of $2.8 million compared to a profit in the prior year period.

earnings miss
60%
bearishMay 7

Gross margins declined from 73% to 66% due to acquisition integration costs.

margin compression
70%
bullishMay 7

Successful integration of Enfusion and Beacon drove a 74% revenue increase.

acquisition
80%
neutralMay 7

Utilized a new $800M+ credit facility to fund growth, significantly increasing interest expense.

debt restructure
50%
bearishMay 7

Company reported a net loss of $2.8 million compared to a profit in the prior year period.

earnings miss
60%
bearishMay 7

Gross margins declined from 73% to 66% due to acquisition integration costs.

margin compression
70%
bullishMay 7

Successful integration of Enfusion and Beacon drove a 74% revenue increase.

acquisition
80%
neutralMay 7

Utilized a new $800M+ credit facility to fund growth, significantly increasing interest expense.

debt restructure
50%

Filing History

10-QMay 7, 2026
Expand Sequence

The Q1 2026 filing presents a company at a critical inflection point, balancing aggressive inorganic growth against deteriorating margins. The 74% revenue jump is an undeniable signal of market demand and successful acquisition execution, yet the transition to a debt-funded growth model has introduced substantial volatility to the bottom line. The shift from a high-margin, organic grower to a consolidating powerhouse has temporarily eroded the company's profitability profile, replacing net income with a reliance on Adjusted EBITDA to prove viability. Ultimately, the investment thesis now hinges on the successful closure of the $8.4 billion merger and the ability of management to realize synergies from the Enfusion and Beacon deals. If the company can stabilize gross margins and leverage its $10 trillion asset base to drive cross-selling, the current losses will be viewed as a necessary investment in scale. However, if regulatory hurdles delay the merger or if integration costs continue to outpace revenue gains, the company faces a challenging path to returning to GAAP profitability.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.